AstraZeneca gets further approval for Tagrisso in Japan

AstraZeneca received approval from the Japanese regulator following a priority review of Tagrisso (osimertinib) as a first-line treatment of patients with positive non-small cell lung cancer (NSCLC), further expanding its currently authorised use in this country.